Across TCGA pan-cancer cohorts, ELOCP16 RNA is linked to patient survival in 1 of 34 cancer types, making it the most broadly survival-associated ELOCP16 data layer.

The strongest signal is observed in acute myeloid leukemia (LAML), where higher ELOCP16 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated ELOCP16 expression acts as an unfavorable survival marker.

LAML are the cancer types where ELOCP16 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LAML	DFS	Tertile	All	0.140	0.582	.020	36	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: ELOCP16 tumor-vs-normal RNA expression · all ELOCP16 data types